Introduction {#s1}
============

Significant memory concern (SMC; also known as subjective cognitive decline (SCD) or subjective memory impairment), is defined as a self-reported cognitive complaints in the absence of objective cognitive deficits, which is common in older adults (Jessen et al., [@B14]; Jenkins et al., [@B13]). Recent mounting evidences indicated that SMC is a risk factor for future accelerated cognitive decline and progression to preclinical or clinical state of Alzheimer's disease (AD), with AD-type changes in amyloid deposition, neuroimaging and cerebrospinal fluid (CSF) biomarkers (Petersen, [@B26]; Visser et al., [@B42]; Reisberg et al., [@B29]; Perrotin et al., [@B25]; Scheef et al., [@B33]; Wang et al., [@B43]; Mitchell et al., [@B21]). Taken together, these results suggested that SMC might be an initial symptomatic indicator of preclinical AD (Jessen et al., [@B14]).

Gender-specific discrepancies in mild cognitive impairment (MCI) and AD have been observed (Roberts et al., [@B31]; Lin et al., [@B19]). Thus, sex-specific research in SMC is crucial to ensure early correct detection and pre-clinical intervention. However, to date, few studies have focused on the role of gender in SMC across a comprehensive profile of the cognitive assessment, neuroimaging and CSF AD biomarkers.

Therefore, the purpose of the current study was to go further to analyze whether the gender discrepancies are related to neuropsychological performance, CSF and positron emission tomography (PET) and magnetic resonance imaging (MRI) biomarkers of AD pathology in older adults reporting SMC.

Materials and Methods {#s2}
=====================

ADNI Study Design {#s2-1}
-----------------

Data used in the preparation of this article were obtained from the AD Neuroimaging Initiative (ADNI) database[^1^](#fn0001){ref-type="fn"} during January 2018. The data collectors were blind to participant information during the experiments. The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial MRI, PET, other biological markers and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. The Principal Investigator of this initiative is Michael W. Weiner, MD, VA Medical Center and University of California-San Francisco. ADNI is a global research effort that actively supports the investigation and development of treatments that slow or stop the progression of AD and subjects have been recruited from over 50 sites across the US and Canada. The overall goal of ADNI is to determine biomarkers for use in AD clinical treatment trials. To date, it has three phases: ADNI1, ADNI GO and ADNI2, consisting of cognitively normal (CN) individuals, early MCI (EMCI), to late MCI (LMCI), and dementia or AD. For more information, see [www.adni-info.org](http://www.adni-info.org). This study was carried out in accordance with the recommendations of each ADNI site. The protocol was approved by the ADNI. All subjects gave written informed consent in accordance with the Declaration of Helsinki.

Subjects {#s2-2}
--------

The current study sample consisted of 69 ADNI-2 participants, including 29 males and 40 females. Participants were selected if they were diagnosed as having SMC. Diagnosis was made using the standard criteria described in the ADNI-2 procedures manual[^2^](#fn0002){ref-type="fn"}. Briefly, SMC participants had subjective memory concerns as evaluated using the Cognitive Change Index (CCI; total score from first 12 items \>16), which was based on selected items from a larger compilation of measures analyzed in an independent sample (Saykin et al., [@B32]), but no informant-reported memory complaints, and normal cognitive performance on the Wechsler Logical Memory Delayed Recall (LM-Delayed) and the Mini-Mental State Exam (MMSE).

Neuropsychological Assessment {#s2-3}
-----------------------------

All participants underwent a standardized cognitive evaluation including the following items: (1) Global cognitive function: MMSE (Folstein et al., [@B8]), Montreal Cognitive Assessment (MoCA; Nasreddine et al., [@B24]), AD Assessment Scale-cognitive subscale 13 (ADAS-13; Mohs et al., [@B22]), Global Clinical Dementia Rating Scale (CDR-SB; Morris, [@B23]); (2) Memory: the Rey Auditory Verbal Learning Test (RAVLT), including trials 1--5 total recall (RAVLT-5 sum), 5-min delayed recall (RAVLT-immediate recall), 30-min delayed recall (RAVLT-delayed recall), yes-no recognition (RAVLT-recognition; Schmidt, [@B34]); (3) Attention/executive function: the Trail Making Test-A and B (TMT-A/B; Reitan, [@B30]); (4) Language: animal fluency, 30-item Boston Naming Task (BNT-30; Domoto-Reilly et al., [@B4]); (5) Visuospatial: clock Drawing Test (CDT; Brodaty and Moore, [@B2]); (6) 15-item Geriatric Depression Scale (GDS-15; Yesavage et al., [@B44]), Functional Assessment Questionnaire (FAQ; Pfeffer et al., [@B28]), Neuropsychiatric Inventory (NPI; Cummings et al., [@B3]).

Apolipoprotein E Genotyping {#s2-4}
---------------------------

Apolipoprotein E (APOE; gene map locus 19q13.2) genotypes of the study subjects were obtained from the ADNI database^1^. All subjects were classified as APOE ε4 carriers with phenotypes ε2/ε4, ε3/ε4, and ε4/ε4, APOE ε4 non-carriers group with ε2/ε2, ε2/ε3 and ε3/ε3 genotypes.

Detection of CSF Aβ42, Tau and P-tau {#s2-5}
------------------------------------

The CSF Aβ42, Tau and P-tau immunoassays were used following a Roche Study Protocol at the University of Pennsylvania/ADNI Biomarker Laboratory, according to the preliminary kit manufacturer's instructions, as described in previous studies (Bittner et al., [@B1]). Values are given in pg/mL for both tau and Aβ42.

\[^18^F\] AV 45 (Florbetapir) PET Scans {#s2-6}
---------------------------------------

\[^18^F\] AV 45 (Florbetapir) PET data were processed and acquired as described previously (Landau et al., [@B18], [@B17]). Mean florbetapir standard uptake value ratios (SUVRs) were measured within four regions (frontal, anterior cingulate, precuneus, and parietal cortex) and normalized to the whole cerebellum reference region. Participants were classified as amyloid positivity when the SUVRs were \>1.11, and amyloid negativity when the SUVRs were ≤1.11 based on a previously established threshold (Landau et al., [@B16]). For more detailed information about PET protocols and data, see the ADNI website[^3^](#fn0003){ref-type="fn"}.

Quantification of Volumes of Hippocampus, Entorhinal Cortex, Fusiform and Medial Temporal Lobe {#s2-7}
----------------------------------------------------------------------------------------------

The ADNI neuroimaging standardized procedure has been described in great detail elsewhere (Jack et al., [@B12]). ADNI-2 MRI data were acquired on a 3 Tesla MRI scanners using T1-weighted sagittal 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequences. Cortical reconstruction and volumetric segmentation were obtained using FreeSurfer version 5.1 image analysis suite in ADNI 2[^4^](#fn0004){ref-type="fn"} (McDonald et al., [@B20]), as described in previous reports (Fischl et al., [@B5], [@B6]; Fleisher et al., [@B7]; Han et al., [@B10]). In this study, hippocampus, EC, fusiform and medial temporal lobe (MTA) volumes were evaluated. Further details on ADNI imaging protocols can be found at <http://adni.loni.usc.edu/methods/documents/mri-protocols/>.

Statistical Analysis {#s2-8}
--------------------

Demographic and clinical variables were compared between genders in the overall sample using Student's *t*-test by mean ± standard deviation (SD) according to the distribution, Mann--Whitney test for skewed distribution variables by median (M) and interquartile range (IQR), Chi-square test for categorical variables. All statistics were performed using SPSS software (version 23.0; IBM SPSS). All calculated tests were two-sided and statistical significance was set at *P* \< 0.05. Figures were produced using GraphPad Prism 6.

Results {#s3}
=======

Demographic Characteristics by Gender {#s3-1}
-------------------------------------

The overall sample was comprised of 69 participants including 29 males and 40 females were downloaded from the ADNI website. Socio-demographics and clinical characteristics of the study sample are presented in Table [1](#T1){ref-type="table"}. In brief, females were less educated compared to males (*P* = 0.036) and males were reported with more alcohol drinking (*P* = 0.038). No gender differences were found in other variables (all *P* \> 0.05).

###### 

Demographic characteristics of subjects included in the study.

  Characteristics                      Total          Males (*n* = 29)   Females (*n* = 40)   *P* value
  ------------------------------------ -------------- ------------------ -------------------- -----------
  Age, years                           71.6 ± 5.3     72.3 ± 5.7         71.0 ± 5.1           0.318
  Education, years                     16 (16--18)    18 (16--20)        16 (15--18)          0.036
  Race, *n* (% White)                  64 (92.8)      26 (40.6)          38 (59.4)            0.708
  Ethnicity, *n* (% Not Hisp/Latino)   66 (95.7)      29 (43.9)          37 (56.1)            0.363
  Marital status, *n* (% Married)      50 (72.5)      23 (46)            27 (54)              0.278
  Right handedness, *n* (%)            58 (84.1)      26 (44.8)          32 (55.2)            0.280
  APOE ε4 carriers, *n* (%)            25 (36.2)      8 (32)             17 (68)              0.203
  Smoking, *n* (%)                     30 (43.5)      15 (50)            15 (50)              0.239
  Alcohol abuse, *n* (%)               3 (4.3)        3 (100)            0 (0)                0.038
  Hypertension, *n* (%)                35 (50.7)      15 (42.9)          20 (57.1)            0.888
  SBP (mmHg)                           135.4 ± 17.5   132.1 ± 17.6       137.7 ± 17.2         0.191
  DBP (mmHg)                           73.3 ± 8.7     72.9 ± 9.4         73.5 ± 8.3           0.792

*Abbreviations: APOE, apolipoprotein E; DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are described as mean ± SD, median (M) and the interquartile range (IQR) unless otherwise specified. P values tested by Student's t-test, Mann-Whitney test and Chi-square test*.

Cognitive Profiles by Gender {#s3-2}
----------------------------

Gender differences in neuropsychological performances in the study sample are demonstrated in Table [2](#T2){ref-type="table"} and Figure [1](#F1){ref-type="fig"}. Men performed worse on ADAS-13 (*P* = 0.004), while women had statistically significant better cognitive function on RAVLT-5 sum (*P* = 0.021) and RAVLT-immediate recall (*P* = 0.010). However, there were no gender differences in performance on MMSE, MoCA, CDR-SB, RAVLT-delayed recall, RAVLT-recognition, TMT-A, TMT-B, Animals fluency, BNT-30, CDT, GDS-15, FAQ, NPI (*P* = 0.917, *P* = 0.098, *P* = 0.408, *P* = 0.053, *P* = 0.064, *P* = 0.229, *P* = 0.888, *P* = 0.685, *P* = 0.920, *P* = 0.350, *P* = 0.554, *P* = 0.843, *P* = 0.632).

###### 

Clinical assessments by gender.

  Variables                Total           Males (*n* = 29)   Females (*n* = 40)   *P* value
  ------------------------ --------------- ------------------ -------------------- -----------
  MMSE                     29 (29--30)     29 (28--30)        29 (29--30)          0.917
  MoCA                     25.9 ± 2.4      25.4 ± 2.5         26.4 ± 2.3           0.098
  ADAS-13                  8.3 ± 3.7       9.8 ± 3.9          7.3 ± 3.3            0.004
  CDR-SB                   0 (0--0)        0 (0--0)           0 (0--0)             0.408
  RAVLT-5 sum              46.6 ± 9.8      43.4 ± 10.9        48.9 ± 8.3           0.021
  RAVLT-immediate recall   9.3 ± 3.3       8.1 ± 3.6          10.2 ± 2.7           0.010
  RAVLT-delayed recall     7.4 ± 4.0       6.2 ± 4.4          8.2 ± 3.4            0.053
  RAVLT-recognition        14 (12--14.5)   13 (10.5--14)      14 (12.25--15)       0.064
  TMT-A                    32.3 ± 10.6     34.1 ± 12.6        31.0 ± 8.9           0.229
  TMT-B                    82.2 ± 39.3     81.4 ± 32.0        82.8 ± 44.3          0.888
  Animals fluency          20.9 ± 5.0      21.2 ± 4.9         20.7 ± 5.1           0.685
  BNT-30                   29 (28--30)     29 (28--29.5)      29 (28--30)          0.920
  CDT                      5 (4--5)        5 (4--5)           5 (5--5)             0.350
  GDS-15                   1 (0--2)        1 (0.5--1.5)       1 (0--2)             0.554
  FAQ                      0 (0--0)        0 (0--0.5)         0 (0--0)             0.843
  NPI                      0 (0--2.5)      0 (0--3)           0 (0--1.75)          0.632

*Abbreviations: ADAS-13, Alzheimer's Disease Assessment Scale-cognitive subscale 13; BNT-30, Boston Naming Task; CDR-SB, Global Clinical Dementia Rating Scale; CDT, Clock Drawing Test; FAQ, Functional Assessment Questionnaire; GDS-15, Geriatric Depression Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NPI, Neuropsychiatric Inventory; RAVLT, Rey Auditory Verbal Learning Test; TMT, The Trail Making Test. Data are presented as mean ± SD, median (M) and the interquartile range (IQR). P values tested by Student's t-test, Mann-Whitney test*.

![Comparison of neuropsychological measures in men and women with significant memory concern (SMC). Scatter plots displaying cognitive function in males and females. **(A)** Men had significantly worse cognitive function as measured by ADAS-13 (*P* = 0.004). **(B)** Women showed greater advantages on RAVLT-5 sum (*P* = 0.021). **(C)** Women excelled at RAVLT-immediate recall (*P* = 0.010). ADAS-13, Alzheimer's Disease Assessment Scale-cognitive subscale 13; RAVLT, Rey Auditory Verbal Learning Test. *P* values tested by Student's *t*-test. \**P* \< 0.05, \*\**P* \< 0.01.](fnagi-10-00166-g0001){#F1}

CSF Biomarkers {#s3-3}
--------------

There were no significant differences in CSF Aβ42, Tau and P-tau levels between males and females (*P* = 0.264, *P* = 0.454, *P* = 0.353; see Table [3](#T3){ref-type="table"}).

###### 

Measurements of cerebrospinal fluid (CSF) biomarkers, positron emission tomography (PET) and magnetic resonance imaging (MRI) in the subjects.

  Variables                Total               Males (*n* = 29)    Females (*n* = 40)   *P* value
  ------------------------ ------------------- ------------------- -------------------- -----------
  CSF Aβ42 (pg/mL)         1370.6 ± 614.2      1468.2 ± 587.2      1299.9 ± 630.9       0.264
  CSF Tau (pg/mL)          243.3 ± 94.3        233.3 ± 90.6        250.6 ± 97.4         0.454
  CSF P-tau (pg/mL)        22.4 ± 10.1         21.0 ± 9.1          23.3 ± 10.8          0.353
  \[^18^F\] AV45 SUVRs     1.06 (1.01--1.21)   1.01 (0.98--1.09)   1.11 (1.03--1.36)    \<0.001
  Aβ positivity, *n* (%)   23 (33.3)           4 (17.4)            19 (82.6)            0.003
  Hippocampus (mm^3^)      7678.7 ± 911.7      8095.7 ± 950.5      7376.4 ± 760.1       0.001
  Entorhinal (mm^3^)       3905.1 ± 568.2      4215.7 ± 532.8      3679.9 ± 485.1       \<0.001
  Fusiform (mm^3^)         18853.0 ± 2209.3    20071.6 ± 2185.2    17969.5 ± 1782.7     \<0.001
  MTA (mm^3^)              20823.3 ± 2776.2    21863.6 ± 3072.6    20069.1 ± 2296.1     0.007

*Abbreviations: MTA, medial temporal atrophy; SUVR, standardized uptake values ratio. *P* values tested by Student's *t*-test, Mann-Whitney test and Chi-square test*.

Aβ Deposition in Different Groups {#s3-4}
---------------------------------

Significant decreases in \[^18^F\] AV45 SUVRs were found in males compared with females (*P* \< 0.001). Aβ positivity was detected in 17.4% of males, 82.6% of females respectively. The percentage of Aβ positive subjects was significantly higher in females vs. males (*P* = 0.003; Table [3](#T3){ref-type="table"}).

Volumes of Hippocampus, Entorhinal Cortex, Fusiform and Medial Temporal Lobe by Gender {#s3-5}
--------------------------------------------------------------------------------------

The volumes of hippocampus, EC, fusiform, medial temporal lobe (MTA) are illustrated in Table [3](#T3){ref-type="table"}. There were significantly larger volumes of hippocampus, EC, fusiform and MTA in men compared to women (*P* = 0.001, *P* \< 0.001, *P* \< 0.001, *P* = 0.007).

Discussion {#s4}
==========

In the present study, we explored a statistically significant gender discrepancy in cognition function, Aβ deposition and brain volume in older adults with SMC. The results confirmed that women with SMC outperformed men with SMC on the tasks of RAVLT-5 sum and RAVLT-immediate recall, while the advantage was eliminated on the task of RAVLT-delayed recall and a floor effect might limit interpretation. However, we found that men with SMC were associated with worse performance on ADAS-13. No significant differences were observed between males and females on other cognitive domains. Our results are in concordance with previous studies showing that the female advantage in verbal memory task was more apparent than men (Herlitz et al., [@B11]; Sundermann et al., [@B40],[@B41]). These observations suggest that gender discrepancies among SMC subjects might be appropriate to a specific cognitive domain. If so, then implementing sex-adjusted norms in clinical memory tests might ameliorate the diagnostic accuracy in women.

Females with SMC participants showed increased Aβ deposition relative to males. Elevated risk of AD was in women compared to men, although the underlying mechanism remains elusive as previously reported (Seshadri et al., [@B35]). However, we did not discover differences in CSF Aβ42, Tau and P-tau between males and females with subjective cognitive impairment. It is noteworthy that we observed significant reduction in volumetric measurements of hippocampus, EC, fusiform gyrus and MTA in females with SMC subjects. Consistent with the cognitive reserve theory (Klonoff and Landrine, [@B15]; Stern et al., [@B37], [@B38]; Stern, [@B36]), better premorbid performance of women on verbal episodic memory tests might confer an advantage in the ability to maintain normal verbal memory performance despite reduced volumes of hippocampal, EC, fusiform gyrus, MTA and accumulating AD pathology (Sundermann et al., [@B40],[@B41], [@B39]). However, women may have more accelerated decline once neuropathology reached a threshold level (Klonoff and Landrine, [@B15]; Stern et al., [@B37]).

Several limitations should be mentioned in the current study. First, a simple cross-sectional design used in the study does not definitively permit the theory that female advantage in verbal memory may act as a specific form of cognitive reserve, further longitudinal researches would be more necessary to closely confirm the conclusions. Second, The ADNI cohort included a potential selection bias based on the fact that ADNI participants had a high education level (Petersen et al., [@B27]; Grill et al., [@B9]), which may affect the generalizability to a greater population sections. Third, the relatively small group size could limit the interpretation of our results, larger sample of numbers need to be collected in future studies.

Conclusion {#s5}
==========

In summary, the present results highlighted the urgent need to consider the sex differences in cognition evaluation, which contributes to clinical diagnosis even in preclinical stages, such as SMC.
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